Screener
CRISPR Therapeutics CRSP Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net loss | (122,931) | (135,996) |
| Foreign currency translation adjustment | (32) | 41 |
| Unrealized (loss) gain on marketable securities | (6,730) | 2,254 |
| Comprehensive loss | $(129,693) | $(133,701) |
| Net loss per common share — basic | $(1.28) | $(1.58) |
| Basic weighted-average common shares outstanding | 96,051,228 | 85,938,720 |
| Net loss per common share — diluted | $(1.28) | $(1.58) |
| Diluted weighted-average common shares outstanding | 96,051,228 | 85,938,720 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's shares (diluted)?
- CRISPR Therapeutics (CRSP) reported shares (diluted) of 96.1M in Q1 2026.
- How has CRISPR Therapeutics's shares (diluted) changed year-over-year?
- CRISPR Therapeutics's shares (diluted) increased by 11.8% year-over-year, from 85.9M to 96.1M.
- What is the long-term trend for CRISPR Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's shares (diluted) has grown at a 3.2% compound annual growth rate (CAGR), from 312.1M to 354.2M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about CRISPR Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude